What Is a Biologic Drug? Definition, Regulation, and Examples

A biologic drug (or “biological product”) is a medicine manufactured from, or derived from, a living organism — cells, tissue, blood, or a biological process such as recombinant DNA technology — rather than synthesized through defined chemical reactions. Vaccines, blood and blood components, gene therapies, cellular therapies, allergenic extracts, and most monoclonal antibodies and other therapeutic proteins fall under this category. In the United States, biologics are regulated as a distinct product class from conventional drugs, approved under a different statute and a different application type, and they are held to manufacturing controls suited to a product that a chemist cannot fully characterize or reproduce atom-for-atom the way a small-molecule drug can.

This page gives a straightforward answer to what a biologic drug actually is, how it differs from a conventional (“small-molecule”) drug, how it is regulated, and where a research-administration reader — regulatory affairs staff, IRB coordinators, compliance officers, procurement and lab managers — fits into that picture. It then links out to CASRAI’s deeper coverage of the specific regulatory mechanics involved.

What makes a drug “biologic”

The defining feature of a biologic is its origin and structure, not its therapeutic use. A biologic is produced in or extracted from a living system — bacteria, yeast, mammalian cell lines, human or animal tissue, blood — using biotechnology or biological processes, and it is typically a large, structurally complex molecule (a protein, a nucleic acid, a living or genetically modified cell, or a whole virus) rather than a small molecule with a single, precisely defined chemical structure.

That complexity is the reason biologics exist as a separate regulatory and manufacturing category in the first place. A small-molecule drug can usually be fully characterized by its exact chemical structure and reproduced identically by any manufacturer with the right synthesis; a biologic’s structure, activity, and safety depend heavily on the living system and process used to make it, so two manufacturing processes rarely produce a molecule that is truly identical — only “highly similar.” That single fact is what drives almost everything else on this page: the separate approval pathway, the more intensive manufacturing oversight, and why a biologic’s generic-equivalent (a biosimilar) is evaluated differently than a small-molecule generic.

Biologic drug vs. small-molecule drug

This is usually the distinction someone searching “what is a biologic drug” actually needs disambiguated:

• Small-molecule drug — chemically synthesized, low molecular weight, a precisely defined and fully reproducible structure (aspirin, most antibiotics, most oral tablets). Regulated under the Federal Food, Drug, and Cosmetic Act (FD&C Act) via a New Drug Application (NDA). CASRAI covers the vocabulary FDA uses for these products in its New Molecular Entity (NME) and New Chemical Entity (NCE) dictionary terms.
• Biologic drug — produced from a living system, structurally complex, generally administered by injection or infusion (proteins are usually broken down if taken orally). Regulated under the Public Health Service Act (PHS Act) via a Biologics License Application (BLA).

CASRAI’s NDA, BLA, 505(b)(2), and ANDA comparison lays out all four FDA marketing-application pathways side by side, including which product types use which application and the review-timeline differences — the natural next stop if the NDA/BLA distinction above is the piece you actually needed.

How biologic drugs are regulated: the BLA pathway

A biologic drug reaches the U.S. market through a Biologics License Application (BLA), submitted under Section 351 of the Public Health Service Act. Under 21 CFR 601.2, a BLA is defined as a request for permission to introduce, or deliver for introduction, a biologic product into interstate commerce. This is a structurally different legal basis than the NDA pathway drugs use under the FD&C Act, though in practice the two review processes share a great deal — both require substantial evidence of safety and effectiveness from adequate, well-controlled clinical investigations, and FDA’s Center for Biologics Evaluation and Research (CBER) reviews most biologics through the same IND-to-BLA clinical development sequence that CDER uses for INDs and NDAs.

An investigational biologic used in a clinical trial before approval is regulated the same way an investigational drug is: 21 CFR 312.3 defines “investigational new drug” to explicitly include “a new drug or biological drug that is used in a clinical investigation,” and treats “investigational drug” and “investigational new drug” as synonymous terms throughout the IND regulations. In practice, that means a biologic in trials moves through the same IND, Phase 1–3 structure, and the same expedited-review options (such as Breakthrough Therapy Designation) that a small-molecule drug candidate does — the BLA/NDA split matters at the marketing-application stage, not the investigational stage.

Common types of biologic drugs

“Biologic” is a category, not a single product type. It covers a wide range of products, including:

• Vaccines — preparations that stimulate an immune response to a specific pathogen.
• Blood and blood components — whole blood, plasma, and derived products such as clotting factors.
• Gene therapies — products that introduce, remove, or alter genetic material to treat or prevent disease. CASRAI’s FDA Approval for Gene Therapy guide walks through the BLA, CBER review, and Regenerative Medicine Advanced Therapy (RMAT) pathway in detail for this specific biologic category.
• Cellular and gene-modified cell therapies — products made from human cells, including some genetically modified for therapeutic use (e.g., CAR-T therapies).
• Monoclonal antibodies and other therapeutic proteins — engineered proteins designed to bind a specific target, a large and fast-growing share of newly approved biologics.
• Allergenic extracts — used in allergy testing and immunotherapy.

Biosimilars: the “generic” for a biologic

Because two manufacturing processes essentially never produce an identical copy of a large, complex biologic molecule, a biologic’s follow-on version isn’t approved as a generic in the small-molecule sense. Instead, FDA evaluates it as a biosimilar — a biological product shown to be highly similar to, and with no clinically meaningful differences from, an already-approved reference biologic — through the abbreviated 351(k) licensure pathway created by the Biologics Price Competition and Innovation Act. See CASRAI’s FDA Biosimilars (351(k) Pathway) dictionary entry for the operational definition, including the separate, higher bar for an “interchangeable” designation.

Biologic drugs vs. medical devices

Biologics are also worth distinguishing from medical devices, since both sit under FDA’s broader product-safety umbrella and both come up constantly in the same research-administration conversations. A device achieves its primary intended purpose through physical or mechanical means rather than through a chemical or metabolic action in or on the body, and it reaches market through a different pathway entirely — a device is generally “cleared” (510(k)) or “approved” (PMA), while a biologic is “licensed” via a BLA. The two regulatory tracks converge in combination products (a drug-device or biologic-device combination, such as a pre-filled biologic autoinjector), which is where a research-administration reader working across both worlds most often runs into the terminology overlap.

Who in a research organization deals with biologic drugs

For a research-administration audience, “what is a biologic drug” is rarely an abstract question — it usually shows up attached to a specific operational task:

• Regulatory affairs staff preparing or maintaining an IND for an investigator-initiated biologic study, or coordinating with a sponsor’s BLA-track development plan.
• IRB coordinators and compliance staff reviewing protocols for biologic trials, which follow the same Good Clinical Practice framework as any other FDA-regulated human study — see CASRAI’s guide on lab and clinical regulatory compliance for the surrounding GxP context.
• Procurement and lab/pharmacy managers responsible for receiving, storing, and handling investigational biologic product, which is frequently cold-chain-sensitive. CASRAI’s Clinical Trial Pharmacy Supply Checklist covers what a research pharmacy needs on hand to reconstitute and dispense investigational product — including biologics — correctly and under proper documentation.
• Grants and contracts staff budgeting for a biologic-heavy trial, where cold-chain logistics and specialized handling can materially change the cost structure compared with an oral small-molecule study.

Go deeper: CASRAI’s biologic and regulatory-pathway coverage

This page is the entry point. For the specific regulatory mechanics, CASRAI already has deeper, more technical coverage:

• NDA, BLA, 505(b)(2), and ANDA compared — the full set of FDA marketing-application pathways side by side.
• FDA Approval for Gene Therapy — the BLA, CBER, and RMAT pathway for one specific, fast-growing biologic category.
• FDA Biosimilars (351(k) Pathway) — how a biologic’s follow-on product is evaluated and approved.
• FDA Breakthrough Therapy Designation — an expedited-review pathway many investigational biologics use.
• Pharma Cold Chain Logistics and Cold Chain — the temperature-controlled handling many biologics require in practice.

Biologic manufacturing and clinical development also sit inside two broader frameworks worth understanding on their own terms: Good Manufacturing Practice (GMP) governs how a biologic is produced, and Good Clinical Practice (GCP) governs how it is tested in human subjects.

Frequently asked questions

Is a vaccine a biologic drug?

Yes. Vaccines are one of the core categories of biologic products and are licensed by FDA under the same BLA/PHS Act framework as other biologics, reviewed primarily by the Center for Biologics Evaluation and Research (CBER).

What is the difference between a biologic and a biosimilar?

A biologic is the original (reference) product or any product licensed under a BLA. A biosimilar is a specific type of biologic — a follow-on product shown to be highly similar to, with no clinically meaningful differences from, an already-approved reference biologic, licensed through the abbreviated 351(k) pathway rather than a full, standalone BLA.

How are biologic drugs approved?

Through a Biologics License Application (BLA) submitted to FDA under Section 351 of the Public Health Service Act, following clinical development under an Investigational New Drug (IND) application — the same IND-to-marketing-application structure a conventional drug follows under the FD&C Act, just ending in a different application type.

Is insulin a biologic drug?

Yes. Insulin and other therapeutic proteins are biologics, produced from living systems (recombinant bacteria or yeast, in modern manufacturing) rather than chemically synthesized.

What’s the difference between “approved” and “licensed” for a biologic?

In practice they describe the same regulatory outcome. FDA formally “licenses” a biologic under a BLA, while a small-molecule drug is “approved” under an NDA — the terminology reflects the different statutes (PHS Act vs. FD&C Act), not a difference in the rigor of review.